Brief: OncBioMune submits protocol for two phase 2 clinical trials
04/05/2016 13:30
May 4 (Reuters) - OncBioMune Pharmaceuticals Inc OBMP.PK
* OncBioMune submits protocol to principal investigators for
two phase 2 clinical trials of proscavax for prostate cancer
Source text for Eikon: ID:nMKWKbcxha
Further company coverage: OBMP.PK
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Theralink Technologies
See all newsBrief: IMAC Holdings - Theralink Will Merge With Newly-Formed Unit Of IMAC In A Stock-For-Stock Reverse Merger Transaction
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say (updated)
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say
Brief: Theralink Technologies Appoints Faith Zaslavsky As President, COO
Brief: Theralink Technologies Appoints Mattia Cremona As Director Of Its Biopharma Laboratory